<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="HF803558F20F64A2E8F4FA7D36BF661B3" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>117 HR 7400 IH: American Made Pharmaceuticals Act of 2022</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2022-04-05</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">117th CONGRESS</congress><session display="yes">2d Session</session><legis-num display="yes">H. R. 7400</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20220405">April 5, 2022</action-date><action-desc><sponsor name-id="C001119">Ms. Craig</sponsor> (for herself and <cosponsor name-id="M001190">Mr. Mullin</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on <committee-name committee-id="HWM00">Ways and Means</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To direct the Secretary of Health and Human Services to conduct a demonstration program to test providing preferential treatment under the Medicare, Medicaid, and CHIP programs for certain drugs and biologicals manufactured in the United States.</official-title></form><legis-body id="HCB3DAD34C08B40299C16BA95ADF2DB70" style="OLC"><section section-type="section-one" id="H7E4AD314EA524CA78D02934513F37290"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>American Made Pharmaceuticals Act of 2022</short-title></quote>.</text></section><section id="HA2D69AD5E3BE4ACCAFC68A1FF31A08D9"><enum>2.</enum><header>Demonstration program to test providing preferential treatment under the Medicare, Medicaid, and CHIP programs for certain drugs and biologicals manufactured in the United States</header><text display-inline="no-display-inline">Part A of title XI of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1301">42 U.S.C. 1301 et seq.</external-xref>) is amended by inserting after section 1150C the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="HDEE0846A96554E6299F9257719AB8B4C"><section id="H8839B00D64A24DD88DB99C00F5701C95"><enum>1150D.</enum><header>Demonstration program to test providing preferential treatment under the Medicare, Medicaid, and CHIP programs for certain drugs and biologicals manufactured in the United States</header><subsection id="H6C08DFBB8A674009BD4E2F98D4CA0AD0"><enum>(a)</enum><header>In general</header><text>Not later than 1 year after the date of enactment of this section, the Secretary shall conduct a demonstration program (in this section referred to as the <quote>Program</quote>) under which U.S. manufactured drugs are given preference under titles XVIII, XIX, and XXI compared to drugs that are not U.S. manufactured drugs through the use of applicable tools.</text></subsection><subsection id="HF7E0AB99C1994202AE5B1E8C3A7A7365"><enum>(b)</enum><header>Sites</header><text>The Program shall be conducted in at least 8 States.</text></subsection><subsection id="H3DFF16AA99FE405A8CBADFEC86383A13"><enum>(c)</enum><header>Duration</header><text>The Secretary shall conduct the Program for a period of not less than 7 years.</text></subsection><subsection id="HA435DFBA747049B5BC50149F0AEDFA41"><enum>(d)</enum><header>Definitions</header><text>In this section:</text><paragraph id="H55552669B8FE45FF88F0EC622CA2B8B0"><enum>(1)</enum><header>Applicable drug</header><text>The term <quote>applicable drug</quote> means—</text><subparagraph id="HA345FB6BB7D64FEF80C4A6DC25E45E28"><enum>(A)</enum><text>a drug that is approved and marketed under section 505(j) of the Federal Food, Drug, and Cosmetic Act; </text></subparagraph><subparagraph id="HC30D4C4FCA1B44EDB164F85E9010BB39"><enum>(B)</enum><text>a biological product that is licensed and marketed under section 351(k) of the Public Health Service Act; or</text></subparagraph><subparagraph id="HCC13D52C632244569296F46E757886D0"><enum>(C)</enum><text>a critical drug.</text></subparagraph></paragraph><paragraph id="HA29375787C194EFDAD30EC793B140430"><enum>(2)</enum><header>Applicable U.S.-based pharmaceutical company</header><text>The term <quote>applicable U.S.-based pharmaceutical company</quote> means a manufacturer (as defined in section 1860D–14A(g)(5))—</text><subparagraph id="HD54F563981404E1EB8680FB4B127C6AF"><enum>(A)</enum><text>that has a manufacturing location in the United States for an applicable drug; </text></subparagraph><subparagraph id="H0645F7BADB8A465C8DC7D513AD46921F" commented="no"><enum>(B)</enum><text>beginning 3 years after the date of the implementation of the Program, for which at least 50 percent of the starter products, by weight, for the applicable drugs manufactured by manufacturer are derived from countries other than covered nations (as defined in section 4871(d)(2) of title 10, United States Code); and </text></subparagraph><subparagraph id="HADDA16BD9BBF49C4A6ECB1F6EB731AEB"><enum>(C)</enum><text>that, as determined by the Secretary—</text><clause id="H82659D9FF99A474483A66EC95AB878B8"><enum>(i)</enum><text>maintains an appropriate level of transparency on locations of manufacturing; </text></clause><clause id="H8F4233917A7C470A9810123E5CDD379A"><enum>(ii)</enum><text>maintains an appropriate level of diversity in sourcing; </text></clause><clause id="HC4FA31BF8A1344C8BE51ECA7AD1506EF"><enum>(iii)</enum><text>maintains appropriate levels of inventory and emergency reserves; </text></clause><clause id="H5B2442B372EC423FBE77CB98955B5F48"><enum>(iv)</enum><text>has in place an appropriate action plan for increases in demand and for when links in the supply chain break down; and</text></clause><clause id="H33F3240B93CA43E7BB80B0FC83E42BD6"><enum>(v)</enum><text>meets any other characteristics the Secretary determines appropriate. </text></clause></subparagraph></paragraph><paragraph id="H4BBAE5ECFE284720B594E21B803B5DDD"><enum>(3)</enum><header>Applicable tools</header><text>The term <quote>applicable tools</quote> means tools determined appropriate by the Secretary, such as—</text><subparagraph id="HE189FF9579D84C56A3C69C9C3141BF63"><enum>(A)</enum><text>preferential treatment on a formulary;</text></subparagraph><subparagraph id="H2E8FF1D8A32D4B86893C0203794F0929"><enum>(B)</enum><text>providing lower cost-sharing; </text></subparagraph><subparagraph id="HDF08BC7750594EE0A9352D970EDE9741"><enum>(C)</enum><text>waiving rebates under the Medicaid program under title XIX;</text></subparagraph><subparagraph id="HDA7350486D2A4F4890BA3F28825A758A"><enum>(D)</enum><text>establishing a Medicare Star Rating under part D of title XVIII; or</text></subparagraph><subparagraph id="HAB8561F5A45E4D51A13C0654FCAB5D17"><enum>(E)</enum><text>providing bonus payments to providers of services and suppliers under part B of title XVIII. </text></subparagraph></paragraph><paragraph id="HB0810B91B9DE439981589857B437B080" commented="no"><enum>(4)</enum><header>Critical drug</header><text>In this section, the term <quote>critical drug</quote> includes the following:</text><subparagraph id="H47F30FA8911245B0AB04F96559649BF5" commented="no"><enum>(A)</enum><text>A medicine, medical countermeasure, or critical input identified on the list under section 3(c) of Executive Order 13944 of August 6, 2020 (85 Red. Reg 49929; relating to essential medicines, medical Countermeasures, and critical inputs).</text></subparagraph><subparagraph id="H732B8CC6E698435FA6746B784DD13D57" commented="no"><enum>(B)</enum><text>A drug or biological that—</text><clause commented="no" id="HFDBA03E5240D4DFBAD0F126AD137E44A"><enum>(i)</enum><text>is not described in subparagraph (A);</text></clause><clause commented="no" id="H5F446484743941CEAABAA87A646FF20A"><enum>(ii)</enum><text>is approved and marketed under section 505(c) of the Federal Food, Drug, and Cosmetic Act or is licensed and marketed under section 351(a) of the Public Health Service Act (or is an active pharmaceutical ingredient of such a drug or biological); and</text></clause><clause commented="no" id="H484AA931BD7B47CBB84DA7E13B37916F"><enum>(iii)</enum><text>the Secretary determines—</text><subclause id="H74F7639F46EE42BFB3AD630626FD1698" commented="no"><enum>(I)</enum><text>is—</text><item id="H66C73EA3DD0D467EBB00AAE5241E865F" commented="no"><enum>(aa)</enum><text>likely to be needed for use in a public health emergency; or </text></item><item id="H99DA82BE3CA641DD832C8F4052BED80B" commented="no"><enum>(bb)</enum><text>at high risk of short supply; and</text></item></subclause><subclause id="H8560F58ABABD45258CFA7846AD3C45CA" commented="no"><enum>(II)</enum><text>has a vulnerable global supply chain.</text></subclause></clause></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H8B89B4A607BD41389AC3630D40BB6D03"><enum>(5)</enum><header display-inline="yes-display-inline">U.S. manufactured drug</header><text display-inline="yes-display-inline">The term <quote>U.S. manufactured drug</quote> means an applicable drug that is manufactured in the United States by an applicable U.S.-based pharmaceutical company.</text></paragraph></subsection><subsection id="HDC4D01DD316A4CE4AE7143691F6B3B69"><enum>(e)</enum><header>Annual report to Congress</header><text>Not later than 1 year after the date the Secretary implements the Program, and annually thereafter for as long as the Program is being conducted, the Secretary shall submit to Congress a report on activities under the Program, together with recommendations for such legislation and administrative action as the Secretary determines to be appropriate.</text></subsection><subsection commented="no" display-inline="no-display-inline" id="HFCB0538F15294EB1BD6FD7B7AF80A4CB"><enum>(f)</enum><header display-inline="yes-display-inline">Waivers</header><text display-inline="yes-display-inline">The Secretary may waive such provisions of this title and titles XVIII, XIX, and XXI as the Secretary determines necessary in order to implement the Program.</text></subsection><subsection commented="no" display-inline="no-display-inline" id="H0CDACDCB37934941A9D5CDD64743549B"><enum>(g)</enum><header display-inline="yes-display-inline">Administrative funding</header><text display-inline="yes-display-inline">There is authorized to be appropriated to the Secretary such sums as may be necessary for the administrative expenses of carrying out the Program, to remain available until expended.</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></section></legis-body></bill> 

